GoDx
Private Company
Funding information not available
Overview
GoDx is a private, pre-revenue diagnostics company developing point-of-care (POC) molecular tests for infectious diseases, starting with gastrointestinal pathogens and associated antimicrobial resistance (AMR) genes. Its proprietary technology platform aims to enable direct-from-sample, culture-free nucleic acid detection with rapid turnaround, targeting use in clinics, urgent care, and public health settings. The company has secured non-dilutive grant funding, achieved key regulatory milestones like a CLIA waiver, and gained strategic positioning through acceptance into BARDA's Rapid Response Partnership Vehicle (RRPV).
Technology Platform
Proprietary point-of-care molecular diagnostic platform for direct-from-sample, culture-free nucleic acid detection and amplification, coupled with a lateral flow assay readout. Enables rapid identification of pathogens and antimicrobial resistance (AMR) genes.
Opportunities
Risk Factors
Competitive Landscape
GoDx competes in the crowded point-of-care molecular diagnostics market against large, established companies like Abbott (ID Now), BioFire (BioFire FilmArray), and Cepheid (GeneXpert), as well as numerous startups. Its differentiation hinges on a low-cost, direct-from-sample platform specifically integrating AMR detection for GI pathogens, targeting settings outside core laboratories.